FDA panel supports continued testing of pain drugs

(AP) -- A panel of arthritis experts has recommended that the federal government allow continued testing of an experimental class of pain drugs for arthritis, despite links to bone decay and joint failure

The Food and Drug Administration's 21-member panel of arthritis experts voted unanimously that research on the nerve-blocking drugs should continue, with certain to protect patients. Reports of joint failure led the agency to halt studies of the drugs in 2010.

Pfizer, Johnson & Johnson and Regeneron Pharmaceuticals have asked the FDA to lift the moratorium on testing of their drugs.

"There's clearly a worrisome safety signal, but in spite of that I think there's an unmet need in certain patient populations," said panelist Dr. Sherine Gabriel, of the Mayo Medical School of Rochester of Minnesota.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

FDA links once-promising pain drugs to bone decay

Mar 08, 2012

Some of the world's largest drugmakers will face an uphill battle next week in their bid to revive a class of experimental arthritis drugs that have been sidelined by safety concerns for nearly two years.

FDA panel backs Pfizer drug for kidney cancer

Dec 07, 2011

(AP) -- A panel of advisers to the Food and Drug Administration voted Wednesday that the benefits of a Pfizer kidney cancer drug outweigh its risks, according to a company spokeswoman.

FDA panel unanimously votes down Parkinson's drug

Oct 17, 2011

A panel of federal medical specialists has unanimously voted that a drug for Parkinson's disease from Teva Pharmaceuticals has not been shown to slow progress of the debilitating neurological disease.

Recommended for you

Added benefit of vedolizumab is not proven

18 hours ago

Vedolizumab (trade name Entyvio) has been approved since May 2014 for patients with moderately to severely active Crohn disease or ulcerative colitis. In an early benefit assessment pursuant to the Act on the Reform of the ...

Seaweed menace may yield new medicines

Oct 22, 2014

An invasive seaweed clogging up British coasts could be a blessing in disguise. University of Greenwich scientists have won a cash award to turn it into valuable compounds which can lead to new, life-saving drugs.

User comments